BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30

• Press Releases

  Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

  September 2, 2025

   · 

  1 min read
• Press Releases

  Encoded Therapeutics Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for ETX101 in SCN1A+ Dravet Syndrome

  September 2, 2025

   · 

  5 min read
• Press Releases

  United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis

  September 2, 2025

   · 

  12 min read
• Press Releases

  SeqOne Acquires Congenica to Create a Global Leader in AI-Powered Genomic Medicine

  September 2, 2025

   · 

  4 min read
• Press Releases

  Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)

  September 2, 2025

   · 

  8 min read
• Press Releases

  Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study

  September 2, 2025

   · 

  4 min read
• Press Releases

  Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

  September 2, 2025

   · 

  18 min read
• 

  Obesity

  Lilly Ends Two Mid-Stage Trials for Second Oral Obesity Asset

  While Eli Lilly’s orforglipron is full speed ahead for a regulatory filing this year, the pharma is also pushing forward with one more Phase II study of naperiglipron, which uses the same scaffold as Pfizer’s failed obesity drugs danuglipron and lotiglipron.

  September 2, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

  September 2, 2025

   · 

  6 min read
• 

  Cardiovascular disease

  Novo’s Wegovy Cuts Cardio Risk by 57% Versus Tirzepatide

  Novo Nordisk’s Wegovy has been on a winning streak as of late, with a metabolic dysfunction-associated steatohepatitis approval last month and prime position in the oral obesity race.

  September 2, 2025

   · 

  2 min read

   · 

  Tristan Manalac